Ko, Jennifer K. Y. http://orcid.org/0000-0003-0475-0645
Kan, Andrew
Leung, Peter
Lee, Vivian C. Y.
Li, Raymond H. W.
Ledger, William
Ng, Ernest H. Y.
Funding for this research was provided by:
merck
Article History
Received: 17 June 2021
Accepted: 17 October 2021
First Online: 11 December 2021
Declarations
:
: The study was approved by the Institutional Review Board of the University of Hong Kong/Hospital Authority Hong Kong West Cluster (UW 15-547) and IVF Australia Ethics Committee (IRB number 116).
: Not applicable
: Corifollitropin alfa (Elonva®) and follitropin beta (Puregon®) used in Hong Kong were donated by MSD, which was not involved in preparation of the protocol, recruitment of patients, conduct of the study, data analysis and writing up the manuscript. P.L. has received conference support from Merck Sharp & Dohme, Merck Group and Ferring. R.L. has received research grant from Ferring unrelated to this manuscript.